The Journal of Clinical Investigation, Inc. Volume 95, January 1995, [211] [212] [213] [214] [215] [216] [217] [218] Atopic dermatitis (AD)' is a chronic inflammatory disease of the skin that frequently occurs in individuals with a personal or family history of atopy (1) . Although AD is extremely common, affecting 10% of children and nearly 1% of the general population, the mechanism underlying this potentially debilitating chronic skin disease is poorly understood. On skin biopsy, the immunohistopathologic features depend on the stage of the lesion (2) . Early lesions demonstrate marked intercellular edema (spongiosis) of the epidermis with dermal infiltrates of activated T lymphocytes that produce IL-4 and IL-5 (3) (4) (5) (6) . However, as lesions become more chronic, there is hyperplasia of the epidermis, with prominent hyperkeratosis and dermal fibrosis. Inflammatory infiltrates of the dermis in chronic lesions consist predominantly of monocyte macrophages (3) .
Enhanced survival of inflammatory cells in inflamed tissues may be a factor in the establishment of chronic inflammation, and conversely, apoptosis or programmed cell death, of effector cells may contribute to the control or resolution of the inflammatory process (7, 8) . The ability of phagocytes to engulf apoptotic cells so that intracellular contents are contained and not liberated to the extracellular milieu, allows the body to remove recruited effector cells in a noninflammatory manner (9) . Recent data demonstrate that IL-4 enhances apoptosis of normal human monocytes following stimulation, and therefore may play an important role in control or resolution of inflammation (10) .
Since chronic AD is associated with activation of circulating (11) and infiltrating monocytes (12) , but also with increased production of IL-4 (4, 13) we hypothesized that monocytes from AD patients may have a paradoxical response to IL-4 with regard to survival. Indeed, in this study we found that cultures of peripheral blood monocytes from AD patients had a lower incidence of spontaneous apoptosis, and were unresponsive to IL-4-induced apoptosis after stimulation, in marked contrast to the responses of NL monocytes. Furthermore, the data demonstrate that the likely cause of this inhibition of apoptosis and nonresponsiveness to IL-4 is attributable to production of GM-CSF by the circulating monocytes of AD patients. Finally, the demonstration of increased levels of GM-CSF mRNA in the inflammed tissues of AD suggests a role for this cytokine in contributing to the chronicity of this skin disease.
GM-CSF from supernatants of cultured monocytes the Factor test human GM-CSF ELISA test kit (Genzyme Corp.) was used. Reagents employed were mouse monoclonal antibody to rGM-CSF as stationary antibody with rabbit anti-rGM-CSF antibody as a second antibody, and biotin-labeled goat anti-rabbit polyclonal antibody as the third antibody. DME and supplements were purchased from Whittaker M. A. Bioproducts, Inc. (Walkersville, MD). Agarose was obtained from Promega Corp. (Madison, WI); bromphenol blue from Bio Rad Laboratories (Richmond, CA); cDNA for GM-CSF from Glaxo Biogen (Geneva, Switzerland); and enzymes for in situ hybridization studies were purchased from Sigma Chemical Co. (St. Louis, MO).
"LPS-free" HSA was obtained from Biocell Laboratories (Carson, CA). Because LPS can inhibit apoptosis and result in activation of cultured monocytes, every effort was made to minimize exposure to LPS during monocyte isolation and assay procedures. Plasticware and reagents were tested for the presence of LPS with the Limulus amebocyte lysate kit (Associates of Cape Cod, Woods Hole, MA) and in all cases were less than 0.1 ng/ml LPS, a level at which inhibition of monocyte apoptosis ( 14) or activation ( 15 ) is not readily demonstrated.
Monocytes. Whole blood was obtained in accordance with Institutional Review Board approval from 12 healthy adult donors with no personal or family history of atopic disease, and eight adult patients with chronic severe AD involving 20-70% of skin surface area, diagnosed by the criteria of Hanifin and Rajka (16) . All AD patients had coexisting respiratory allergy, either mild allergic rhinitis or asthma, not requiring maintenance medications. None of the AD patients had previously been treated with systemic corticosteroids. Topical corticosteroids were withheld for the 24 h before venipuncture. Additionally, as a skin disease control, monocytes were obtained from four adult donors with psoriasis vulgaris involving 30-60% of body surface area. Peripheral blood mononuclear leukocytes were obtained by discontinuous plasma-Percoll density gradient separation. Monocytes (> 98% viable, > 85% yield) were further isolated by counterflow centrifugation-cell elutriation as has been previously published (15) . Purity of the preparation of monocytes was 91.5 + 1.7 (SD) % as assessed by nonspecific esterase staining and was unchanged at time of harvesting cells from culture. Contaminating cells consisted of granulocytes (0-7%) and lymphocytes (0-6%) without differences between preparations obtained from AD and NL donors. Due to the limited and variable numbers of monocytes obtained from each donor, not all studies could be performed on cells obtained at a given time. For this reason, some donors were used on more than one occasion for different experiments. However, for any given experiment, a total of 3-10 donors were used with each donor studied only once.
Culture and co-culture conditions. Following the method of Mangan et al. (10) , monocytes (2 x 106/0.2 ml) were suspended in DME containing 25 mM glucose, 92 mM gentamicin, 20 mM L-glutamine, and 25 mM Hepes buffer, pH 7.3, in sterile 12 x 75 mm polypropylene tubes. Cultures were incubated in high humidity at 37°C in 7.5% CO2. Cytokines were diluted in media and added in the specified concentrations. For experiments employing GM-CSF, addition of 0.1% HSA to medium was necessary. In these experiments, appropriate controls with and without cytokines, were also incubated in the presence of 0.1% HSA which did not alter monocyte apoptosis in agreement with the findings of Mangan et al. (14) . For co-culture experiments, fresh NL monocytes (10 x 106) were cultured in conditioned media with 0.1% HSA (200 ,l) harvested from AD monocytes (10 X 106) after 4 h incubation. When neutralizing antibody to GM-CSF was added to cocultures, it was added simultaneously with conditioned media at a concentration of 40 [ug/ml.
Morphological appearance of apoptosis. Two methods were used: (a) flow cytometry and (b) light microscopy. For determination of apoptotic cells by flow cytometry, the method of Mangan and Wahl (17) with modifications described below was used. Samples ( 106 cells) were removed from cultures and suspended in media. Cells (20,000 events) were simultaneously analyzed on a 751 flow cytofluorograph (Coulter Electronics, Hialeah, FL) for forward scatter (a measure of cell size) and side scatter (a measure of granularity). Plots allowed separation of two cell populations, one smaller and less granular (apoptotic) and one larger and more granular (nonapoptotic). For determination of percentage of cells having undergone apoptosis by light microscopy, monocytes (105) were harvested, cytospins prepared and stained with leukostat stain kit (Fisher Scientific Co., Pittsburgh, PA). Using the x40 objective, monocytes were scored as apoptotic or nonapoptotic in a blinded fashion by a single investigator (J. M. Kailey). 300 cells were counted from random fields for each specimen and the percent showing the morphological phenotype indicative of apoptosis expressed as a percentage of the total.
DNA fragmentation. The quantity of low molecular weight DNA as percentage of total DNA was determined by diphenylamine reaction as by the method of Burton (18) . Monocytes (3 x 106) were lysed in Tris-Triton EDTA (TTE) and centrifuged at 13,000 g for 10 min at 40C. Pellets were resuspended in TCA (5%) and heated at 90TC for 10 min. Samples were treated with diphenylamine (15 mg/ml), incubated at 220C for 24 h, and read at 570 nm. DNA fragments from 10 x 106 monocytes were further characterized by electrophoresis in 2% agarose at 120 V for 6.5 h as by the method of Sambrook et al. (19) In situ hybridization for GM-CSF mRNA. In situ hybridization was performed as previously described (20) (21) (22) (23) 15 .2±2.9%, respectively, means±SD, P < 0.001 by univariate ANOVA). Monocytes having undergone apoptosis were identified by their shrunken appearance with marked loss of cytoplasm and nuclear condensation (Fig. 1) . All microscopic analyses were done by a blinded observer. Apoptotic monocytes were also quantified by flow cytometry using the method of Mangan et al. (10 (10, 14, 17) , it was of interest to determine whether cytokine stimulation would further inhibit apoptosis in monocytes from AD patients. Stimulation of NL monocytes with either IL-la (Fig. 3) (Fig. 4) .
Evidence that inhibition of monocyte apoptosis is due to endogenous GM-CSF production by monocytes in patients with AD. The paradoxical finding of the lack of responsiveness by AD monocytes to IL-4, a cytokine present in the milieu of AD (4, 5, 13) Fig. 3) . As a proof of concept, cultures of AD monocytes were therefore assessed for evidence of endogenous production of GM-CSF. GM-CSF was detected in four out of four supernatants of cultured AD monocytes and appeared to peak at 4 h of culture at a level of 228±150 (mean±SD) pg/107 monocytes. By comparison, GM-CSF measured in 12 NL culture supernatants was not detectable in six, and found to be 44±58 (mean±SD) pg/107 monocytes in the remaining six cultures (P < 0.05). Additionally, no GM-CSF was detected in the supernatant from monocytes from the four patients with psoriasis. Importantly, skin biopsies of acute and chronic AD, as well as psoriatic lesions and normal skin from NL controls, were examined by in situ hybridization for GM-CSF mRNA. As shown, a significantly greater number of GM-CSF mRNA positive cells (P < 0.05) were identified in lesions of chronic AD than in lesions of acute AD or control skin biopsies from NL donors (Fig. 6) . The GM-CSF mRNA positive cells in chronic AD were distributed mainly in the dermis where monocyte macrophages predominate in chronic AD skin lesions (3) (Fig.  7) . However, the absolute identity of the cells positive for GM-CSF mRNA was not determined in these studies and may include T cells, mast cells, and keratinocytes in addition to the monocyte macrophage. Of note, GM-CSF mRNA positive cells were also present in lesions of chronic psoriasis with similar frequency as compared to that of chronic AD (12.5±3.1 compared to 16 .0±5.0 GM-CSF mRNA positive cells/high power field, means-SD, respectively), demonstrating that GM-CSF produced in tissue is likely to play a role in a variety of chronic skin diseases (see Discussion). Finally, as a test of whether supernatants from cultured AD monocytes could inhibit NL monocyte apoptosis, conditioned media were harvested from 4-h cultures of AD monocytes and used to treat fresh NL monocytes. Indeed, at 48 h, a significant decrease in apoptosis was demonstrated in NL monocytes cultured with AD supernatant as compared to NL supernatant (Fig.  8) . Importantly, the incidence of apoptosis was restored to that seen in control cultures when cultures were treated with AD supernatant and a neutralizing antibody to GM-CSF. Taken together, these data support the hypothesis that AD monocytes both produce, and are stimulated by GM-CSF, and that such stimulation results in dysregulation of both baseline apoptosis, and cytokine (IL-4) induction of apoptosis.
Discussion
Despite the common occurrence of AD in the general population, the events that lead to perpetuation of skin inflammation in this disease are poorly understood. An understanding of this process may provide important new directions for its treatment. Early inflammatory events likely lead to the generation of proinflammatory cytokines and mediators, the upregulation of adhe- cellular matrix markedly enhance both the inflammatory potential and longevity of these recruited effector cells (10, 14, 17, 29, 30) . Though the monocyte macrophage is obviously only one inflammatory cell in the complex inflammatory process described above, the predominance of these cells in the established lesions of chronic AD, and the known proinflammatory activities of these cells suggest they may have an important role in the perpetuation of inflammation in AD (3). Furthermore, the finding of enhanced monocyte longevity presented here may also be applicable to other diseases such as idiopathic pulmonary fibrosis and asthma where monocyte macrophage infiltrates are prominent. The hypothesis that dysregulation of monocyte apoptosis and hence enhanced survival of monocytes occurs in chronic AD, is supported by the data presented in this paper. Specifically, our data demonstrate that cultures of peripheral blood monocytes of AD patients exhibit decreased numbers of cells undergoing apoptosis when compared to cultures of normal monocytes (Fig. 3) and monocytes obtained from patients with psoriasis. Furthermore, the inhibition of apoptosis in NL monocytes, both baseline and cytokine (IL-4)-induced, following treatment with either GM-CSF (Fig. 5) or conditioned media from AD monocytes (Fig. 7) , suggested that the difference in GM-CSF production between NL and AD monocytes is the basis for these phenomena. Heightened secretion of GM-CSF from circulating AD monocytes in comparison to that of NLs and psoriasis patients, and the finding of increased levels of GM-CSF mRNA expression by in situ hybridization in the inflammatory cell infiltrate of chronic AD, as compared to the acute AD skin lesion (Fig. 6) , was demonstrated. These data support the hypothesis that monocytes in AD are uniquely stimulated by GM-CSF in the blood, by either an autocrine or intracrine mechanism, and also stimulated by GM-CSF in the tissues of AD. Thus, this cytokine may be important in development of long-standing AD inflammation. Additionally, the finding of increased GM (4) . Furthermore, the presence of elevated IgE production from B cells which can be blocked by anti-IL-4, and the presence of CD23 on monocytes and other cells are likely consequences of in vivo IL-4 production in AD (32) (33) (34) .
The finding that monocytes from AD patients do not undergo apoptosis to IL-4 after stimulation was a novel and surprising finding in this study and suggests that this anti-inflammatory effect of IL-4 is not manifest in AD, despite the fact that other pro-inflammatory activities of IL-4 predominate. The demonstration that GM-CSF treatment of NL monocytes results in abrogation of IL-4-induced monocyte apoptosis, taken together with the evidence for the presence of GM-CSF in AD may suggest one mechanism for perpetuation of the skin inflammation in AD. The complete restoration of apoptosis in NL monocytes co-cultured with AD-conditioned media after the addition of neutralizing antibody to GM-CSF is strong evidence that GM-CSF alone, and not another cytokine, is responsible for the demonstrated monocyte longevity.
The altered cytokine responses and GM-CSF production by circulating AD monocytes presented here are consistent with previous studies demonstrating activation of circulating monocytes in AD. Previous data demonstrating that circulating monocytes are primed for superoxide production (11), may also be a consequence of generation of GM-CSF (35) . GM-CSF has also been reported to induce CD23 expression on peripheral blood monocytes (26) . The increased production of GM-CSF in AD may also contribute to the increased eosinophilia and deposition of eosinophil granule proteins in this disease (36) (37) (38) . At present, the mechanism for increased GM-CSF production by monocyte macrophages is not well understood. One likely possibility, however, may relate to increased allergen and/or staphylococcal toxin exposure as both stimuli can act as macrophage activators and are known triggers for AD (12 
